Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. - Wikidata - awgldk - TriplyDB

Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status.

Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status.

http://www.wikidata.org/entity/Q36901561

about

Neurodegenerative disease mutations in TREM2 reveal a functional surface and distinct loss-of-function mechanisms sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers.Expression and processing analyses of wild type and p.R47H TREM2 variant in Alzheimer's disease brains.The APOE ε4 genotype modulates CSF YKL-40 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2.Increase of TREM2 during Aging of an Alzheimer's Disease Mouse Model Is Paralleled by Microglial Activation and Amyloidosis.A data-driven approach links microglia to pathology and prognosis in amyotrophic lateral sclerosis TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury.The FTD-like syndrome causing TREM2 T66M mutation impairs microglia function, brain perfusion, and glucose metabolism.Rare TREM2 variants associated with Alzheimer's disease display reduced cell surface expression Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury.Soluble TREM2 induces inflammatory responses and enhances microglial survival.TREM2 in Neurodegenerative Diseases.TREM2-Ligand Interactions in Health and Disease.A split-luciferase complementation, real-time reporting assay enables monitoring of the disease-associated transmembrane protein TREM2 in live cells.Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers.Applying fluid biomarkers to Alzheimer's disease.Untangling Genetic Risk for Alzheimer's Disease.Triggering Receptor Expressed on Myeloid Cells-2 (TREM-2) expression tracks with M2-like macrophage activity and disease severity in COPD.TREM2 shedding by cleavage at the H157-S158 bond is accelerated for the Alzheimer's disease-associated H157Y variant.Microglia-Synapse Pathways: Promising Therapeutic Strategy for Alzheimer's Disease.CSF sTREM2: marking the tipping point between preclinical AD and dementia?An Alzheimer-associated TREM2 variant occurs at the ADAM cleavage site and affects shedding and phagocytic function.Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.Microglia and Aging: The Role of the TREM2-DAP12 and CX3CL1-CX3CR1 Axes.An early and late peak in microglial activation in Alzheimer's disease trajectory.TYROBP genetic variants in early-onset Alzheimer's disease.Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer's disease.Assessment of the Genetic Architecture of Alzheimer's Disease Risk in Rate of Memory Decline.Integrated biology approach reveals molecular and pathological interactions among Alzheimer's Aβ42, Tau, TREM2, and TYROBP in Drosophila models.NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.The Past and the Future of Alzheimer's Disease Fluid Biomarkers.Soluble TREM2 and biomarkers of central and peripheral inflammation in neurodegenerative disease.Molecular biomarkers of Alzheimer's disease: progress and prospects.TREM2 regulates innate immunity in Alzheimer's disease.Genetic study of multimodal imaging Alzheimer's disease progression score implicates novel loci.Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup Glycoprotein NMB: a novel Alzheimer's disease associated marker expressed in a subset of activated microglia CSF sTREM2 in delirium-relation to Alzheimer's disease CSF biomarkers Aβ42, t-tau and p-tau Human Induced Pluripotent Stem Cell-Derived Microglia-Like Cells Harboring TREM2 Missense Mutations Show Specific Deficits in Phagocytosis Microglial TREM2/DAP12 Signaling: A Double-Edged Sword in Neural Diseases

P2860

Q31814881-732600AA-D14C-402E-B678-F4A688185F61 Q35945633-0925633D-F8FA-4456-8AE9-8660FB9F737C Q36204253-227C3274-7F79-4194-8DF9-55FA4FB3F747 Q36266994-F0FF6061-BD61-427B-96ED-8A6C1F3F8E4D Q36280558-2103072F-EC2D-46A7-9F56-CCD4B37F359F Q36311348-3F4FCB00-67ED-40D0-BA03-B93F691279F7 Q36366427-C65814AD-D089-483E-82F4-01A03999CF25 Q36385532-6C71F0FB-1950-4197-A824-524764CC9423 Q37230891-E332CAA0-3EDF-4606-97E0-067DA09232A2 Q37743591-DA4EBAC5-98E8-4351-9D1C-D83351CF2DF7 Q38402630-AEB8CC15-3822-408D-A294-F3314144CE78 Q38646212-FE8D62D5-FF5C-4FBE-89BE-87870C19CBC1 Q38692159-ED4EAF1D-6D56-45EF-9416-19EB149648DA Q38704022-40CC7FBC-3844-45F5-BB03-E67D567F9EEE Q38752201-926643B6-0431-42BA-B844-CCA0C476FAC0 Q39251035-B3199259-44E9-439B-820B-4B0D1242B974 Q39407560-55A2C5E3-574D-4D7E-82F5-BF2246BDBF5C Q41919811-3BBEFFFD-786A-43A5-AC08-8D817CD7C5E8 Q41997591-A67FCB45-2367-4DDF-8D7F-78E463C74A6B Q42038294-6657F6B9-E645-4CDE-9559-507E0C3A5317 Q42064656-1124D0F1-6931-4EE5-AE10-FEFF0E6898B9 Q42091243-FB250A90-0E07-420B-80D0-1BF31D560847 Q47587631-21EC9192-29A1-40B7-9C0F-4A583D1B4295 Q47844298-37676BB8-8DE0-4E3B-B2EF-BBA8F4FB20AE Q48339994-3669A6CC-5D61-4647-8F5C-BE51FE52C9F3 Q50282338-1A03BF71-0438-44BC-A71C-94EEA58CB3CE Q50331861-08CCAE6A-8859-4FF4-A01D-8FDAD633E470 Q50534616-C94F144C-7DC3-4107-97CA-82F528B83C62 Q51758354-CB962FF8-C95B-4FB0-BED0-AA11E4BA6D3D Q52589491-6149B903-9AAE-4704-BFE6-9F864646542A Q52644601-47C7D52A-C933-4FD5-866E-E35FFE35666E Q52717313-1BB89BB4-7478-4403-B6E1-B95881264173 Q54946040-C7B1CF53-5B40-4742-8323-371734E0D53F Q55158988-B1AD84F3-9EC7-4546-ABC8-1BA165D46E7A Q55514197-88ADAA12-14D8-4827-8E97-E72171E20172 Q57168893-337354FE-AAA8-414C-885C-FE57D368F543 Q57809060-CCDF5532-E0A1-48D9-B9AB-DCC193470DCF Q58614421-20CB2128-3893-4962-BE2F-0B3E4F076036 Q58697755-A67D6C8A-BB85-46D7-BF15-5B35C61A20C6 Q58799111-E841EF59-DC0B-40E5-BB3B-A3C0AD140863

P2860

Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status.

http://www.wikidata.org/entity/Q36901561

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Cerebrospinal fluid soluble TR ...... sociated with mutation status.

@en

type

label

Cerebrospinal fluid soluble TR ...... sociated with mutation status.

@en

prefLabel

Cerebrospinal fluid soluble TR ...... sociated with mutation status.

@en

P1433

Q36901561-2D8626FA-BC95-4ABB-A85C-542BC2BE046F

P1476

Q36901561-796B33F1-21B3-49E8-8E23-911103327FBF

P2093

Q36901561-682EA8FF-2313-422C-9890-EE3635851E90

Q36901561-D4A7E2A9-9F64-4ABE-8AE6-8E78FE9D3AB9

Q36901561-DB90FB91-9004-4119-9FA0-B4DD987BBF35

Q36901561-DD8DA758-E615-41AA-813E-386A7B1CD79F

P2860

Q36901561-04337FAA-9CCF-467D-B27E-527685EB590D

Q36901561-09877C7A-D5C8-4AC0-BA98-97A0A67A7D39

Q36901561-0D70ED6A-FAF6-43C6-B524-80DB84C27E5E

Q36901561-10E711F2-DFFD-408A-95BA-BB5F3CD63040

Q36901561-1624EF8D-925A-4E0E-B203-538B8AC8336C

Q36901561-1D6D927B-0CEB-42E5-97A0-426C2E8E3691

Q36901561-1FF1B0A5-921A-46AC-A199-6FE8C6710527

Q36901561-20DD41E9-A705-4705-9A7B-E0D2E8E45664

Q36901561-232542BB-CBDD-4C76-A650-677718A095AC

Q36901561-2499FF02-5BDC-4966-BE12-0E3B528E61EF

P2888

Q36901561-2C72F51A-C482-4D5A-8A82-6922D97F9FEC

P304

Q36901561-40D35537-66CF-4BD8-8FED-274E1F33FE11

P31

Q36901561-5C2F6D8A-2DEE-4204-817D-3D5F3A25E134

P356

Q36901561-D74F9A2D-DA83-4800-B7D8-BE208DEA61BB

P433

Q36901561-1A126C02-2E70-45C5-AB34-4AC112A89DF3

P478

Q36901561-E41EF12D-C08F-44D6-974D-03BA851E91B7

P50

Q36901561-03CC17C8-D889-4F19-9D39-FAC6956BA30F

Q36901561-0F02F1D7-276D-4074-BCCA-6F4AA0501935

Q36901561-5AFBB9BF-FC5F-4041-A195-80BBC2A8543F

Q36901561-5FAD8BFB-5338-42CD-AA38-F0AB0922E306

Q36901561-C17AD751-2D58-4C62-9942-6EA9EB6AAF59

Q36901561-FAC82B03-EEF3-4834-97CA-02BB8C5017CF

P577

Q36901561-BBD57F0E-A915-4347-9E0C-B596D1A0E011

P698

Q36901561-D74F3F51-20DD-4DFD-9AF7-83023C79789C

P921

Q36901561-3234D331-1184-440B-8155-4DD01492C7CE

Q36901561-B0C94DD7-B115-4106-8D2F-BBDD325F605C

P932

Q36901561-A16D3261-A43B-43A0-BCB0-F92D8DC207A0

P356

S00401-016-1533-5

P1433

Acta Neuropathologica

P1476

Cerebrospinal fluid soluble TR ...... sociated with mutation status.

@en

P2093

Carlos Cruchaga

http://www.w3.org/2001/XMLSchema#string

Daniela Galimberti

http://www.w3.org/2001/XMLSchema#string

Jorge L Del-Águila

http://www.w3.org/2001/XMLSchema#string

Laura Piccio

http://www.w3.org/2001/XMLSchema#string

P2860

TREM2 Variants in Alzheimer's Disease

Variant of TREM2 Associated with the Risk of Alzheimer's Disease

Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease

Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype

Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation

An Italian family affected by Nasu-Hakola disease with a novel genetic mutation in the TREM2 gene

Novel compound heterozygous mutation in TREM2 found in a Turkish frontotemporal dementia-like family

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Neuropsychological tests and functional nuclear neuroimaging provide evidence of subclinical impairment in Nasu-Hakola disease heterozygotes

Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement

P2888

s00401-016-1533-5

P304

925-933

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00401-016-1533-5

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

131

http://www.w3.org/2001/XMLSchema#string

P50

David M. Holtzman

Barbara Borroni

Chiara Fenoglio

P577

2016-01-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26754641

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

cerebrospinal fluid

P932

4867123

http://www.w3.org/2001/XMLSchema#string